Biocytogen and CtM Bio Advance in Developing Multi-Specific T Cell Engager against WT1/HLA-A02

28 December 2023 | Thursday | News


Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd ("CtM Bio") jointly announce that the development of a tri-specific T cell engager for an intracellular target achieved milestone progress.
Image Source : Public Domain

Image Source : Public Domain

In just one year since the start of the collaboration, the companies have identified a WT1/HLA-A02-specific T cell engager (WT1xCD3x4-1BB tri-specific antibody) with outstanding preclinical anti-tumor activities for both hematological malignancies and solid tumors. The incorporation of the T co-stimulatory signal for WT1-targeting T cell engager further gives it the best-in-class properties and first-in-class potential. Its preclinical data has been accepted for presentation at the upcoming 2024 AACR annual meeting.

WT1 (Wilms’ tumor gene 1) is an intracellular protein highly enriched in certain cancer cells compared to normal tissues, making it an attractive tumor target for cancer immunotherapy. To identify novel WT1-targeting antibody-based therapeutics, Biocytogen harnessed its RenTCR-mimicTM mice and high-throughput in vivo and in vitro screening platforms to successfully generate WT1 antibodies with superior specificity and high affinity to the HLA/peptide complex. These antibodies were further engineered using CtM’s state-of-the-art T cell engager technology, which is specifically designed to overcome T cell over-activation toxicity and prevent T cell exhaustion, leading to highly effective, safe and controllable multi-specific engagers.

Dr. Yuelei Shen, President and CEO of Biocytogen, said, “Our collaborative efforts with CtM Bio have progressed rapidly, resulting in the identification of novel immunotherapies targeting WT1. This rapid and effective development of multi-specific T cell engagers undoubtedly validates CtM Bio’s advanced T-cell engager technology, along with our expertise in discovering fully human TCR-mimic antibodies against intracellular targets. We anticipate advancing this preclinical candidate into clinical trials soon, providing treatment options for patients with acute myeloid leukemia, ovarian cancer, and various solid tumors.”

Dr. Lei Fang, Vice President of Lepu Biopharma and CEO of CtM Bio, said, “The combination of Biocytogen’s streamlined fully human antibody discovery capabilities and CtM Bio’s deep understanding of immune cell engagers have greatly accelerated our development of differentiated T cell engagers targeting WT1. We look forward to continued collaborations to further develop this candidate and initiate clinical trials. Together, we aim to usher in a new era of therapies targeting intracellular tumor antigens and broaden the applications of T cell engagers for the treatment of solid tumors, which will ultimately offer new opportunities for cancer patients.”

 

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close